Whether it is an elderly German man who lost his job or a young boy that reached Europe fleeing war at home, Europe’s excluded are falling through the cracks of healthcare systems, writes Médecins du Monde.
Following a clash with the Greek government over its decision to withdraw a cancer drug from the market, ROCHE, a Swiss multinational company, ultimately decided to make the drug available to patients for free.
Several pharmaceutical companies in Greece have threatened to stop supplying the market with innovative drugs and said they could even withdraw existing drugs as a result of an obligatory “discount” imposed by the Greek government and applied retroactively.
Marc-Alexander Mahl is President of Medicines for Europe.
Europe’s healthcare model is under pressure. Populations are ageing in Europe – with the number of Europeans aged 65 or over set to rise by 45 million between 2015 and 2050.(1) This brings with it greater healthcare costs: currently, around 50 million EU citizens are estimated to suffer …
Organisations of patients with rare diseases have warned EU policymakers to “think carefully” before reviewing the incentives in the orphan drugs regulation, claiming that the pharma industry should not be discouraged from investing in new therapies.
“Salami-slicing” the cost of medicines, which represent almost one-fifth of health system budgets and are subject to rigorous value assessments, won’t make healthcare systems more sustainable in the future, Nathalie Moll told EURACTIV.com in an interview.
The European Medicines Agency approved 39 new cancer drugs between 2009 and 2013 despite having no evidence that they worked, unnecessarily exposing patients to toxicity, researchers said Thursday (5 October).
Makers of spirits and beer are exploring self-regulatory solutions to show consumers the ingredients contained in the alcohol they drink. However, they find the Commission's timeline "too tight" and fear mandatory rules will eventually be imposed on them.
People on the bottom rung of the socioeconomic ladder may live two years less on average than those at the top, according to a large-scale study published Wednesday (31 January) in the British journal The Lancet.
We are halfway through this European Parliament’s mandate and, as ever, many laws have been voted, with many more to come. But will they be effectively introduced at the national level in the area of health? Denis Horgan asks.
There is a great need to raise awareness and enhance education on diabetes and a healthier lifestyle “at every level”, Stella de Sabata, head of the International Diabetes Federation, told EURACTIV.com.
The introduction of digital technology in healthcare systems might be viewed by health stakeholders in a positive light. However, policymakers are yet to address issues related to data collection and use that are considered crucial in the management of chronic conditions like diabetes.